Analysts Expect Dicerna Pharmaceuticals, Inc. (DRNA) to Announce -$0.64 EPS
Analysts expect Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to post earnings of ($0.64) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Dicerna Pharmaceuticals’ earnings. The highest EPS estimate is ($0.28) and the lowest is ($0.80). Dicerna Pharmaceuticals posted earnings of ($0.68) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 5.9%. The firm is expected to announce its next quarterly earnings report on Thursday, March 29th.
Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.22). Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The business had revenue of $0.47 million during the quarter. During the same quarter last year, the firm posted ($0.68) EPS. The business’s revenue was up 192.6% on a year-over-year basis.
Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) traded up $0.41 on Thursday, hitting $8.48. The stock had a trading volume of 237,015 shares, compared to its average volume of 176,801. Dicerna Pharmaceuticals has a one year low of $2.42 and a one year high of $10.24.
A number of hedge funds have recently modified their holdings of DRNA. Northern Trust Corp grew its position in Dicerna Pharmaceuticals by 6.1% during the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 2,094 shares during the last quarter. Bourgeon Capital Management LLC grew its position in Dicerna Pharmaceuticals by 188.9% during the 2nd quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 25,500 shares during the last quarter. Birchview Capital LP grew its position in Dicerna Pharmaceuticals by 125.0% during the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock worth $259,000 after acquiring an additional 25,000 shares during the last quarter. Deschutes Portfolio Strategy LLC bought a new stake in Dicerna Pharmaceuticals during the 3rd quarter worth $575,000. Finally, Vanguard Group Inc. grew its position in Dicerna Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after acquiring an additional 14,517 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.